SecBot SecBot
8-K ·Filed May 4, 2026

COAG

Hemab Therapeutics Holdings, Inc.
NEUTRAL
Impact 4/10
Horizondays Processed6mo ago SEC0001193125-26-203988
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

Monitor the company's first earnings report as a public company for guidance on revenue trajectory and pipeline progress. The IPO provides a cash runway but no revenue or profitability metrics were disclosed in this filing.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$25.00
T+0 close · May 4, 2026 · via day close
Latest settled
+89.88%
T+60 · $47.47
Vs SPY
+87.14%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 5 $25.00entry
  2. T+1 · 7mo ago +0.04%α −1.34% · $25.01
  3. T+5 · 6mo ago +3.60%α +1.62% · $25.90
  4. T+20 · 6mo ago +9.88%α +4.93% · $27.47
  5. T+60 · 4mo ago +89.88%α +87.14% · $47.47

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Hemab Therapeutics completed its IPO of 19,262,500 shares at $18.00/share, raising $346.7M in gross proceeds. Concurrently, the company adopted a restated certificate and bylaws with standard public-company governance provisions (classified board, supermajority voting, exclusive forum). This is a routine post-IPO administrative filing with no new financial data or operational updates.

Key Facts

  • IPO closed on May 4, 2026, with 19,262,500 shares sold including full exercise of underwriter option
  • IPO price: $18.00 per share
  • Gross proceeds: $346.7 million before underwriting discounts and expenses
  • Restated certificate increases authorized common stock to 400,000,000 shares and authorizes 5,000,000 shares of undesignated preferred stock
  • New governance features: classified board, director removal only for cause with 75% supermajority vote, no stockholder action by written consent, exclusive forum provisions

Financial Impact

IPO raised $346.7 million in gross proceeds; net proceeds will be lower after underwriting discounts and expenses (not specified)

cashsharesOutstanding

Risk Factors

  • Pre-revenue biotech with no approved products or disclosed financial performance
  • Governance changes (classified board, supermajority requirements) reduce stockholder influence and could deter activist investors
  • Potential dilution from authorized but unissued preferred stock

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-203988
Document: d149100dex31.htm0001193125-26-203988
Document: d149100d8k.htm0001193125-26-203988
Document: 0001193125-26-203988-index-headers.html0001193125-26-203988
Document: 0001193125-26-203988-index.html0001193125-26-203988
Document: 0001193125-26-203988.txt0001193125-26-203988

Track record

19 reports on COAG

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 10, 20266d ago Press Release Neutral 4/10 Entry $38.77 Now $39.06 +0.75% settles Nov 17
  2. Nov 9, 20267d ago Press Release Bullish 6/10 Entry $42.81 to $39.06 Now $39.06 −8.76% ▼ −8.77% −7.08% vs SPY
  3. Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $49.02 to $40.86 Now $39.06 −20.32% ▼ −16.65% −19.24% vs SPY
  4. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $45.09 to $39.33 Now $39.06 −13.37% ▼ −12.77% −11.86% vs SPY
  5. Sep 25, 20267w ago 3 Neutral 2/10 Entry $33.12 to $30.59 Now $39.06 +17.93% ▼ −7.64% −8.84% vs SPY
  6. Sep 17, 20268w ago Press Release Neutral 4/10 Entry $41.22 to $35.72 Now $39.06 −5.24% ▼ −13.34% −14.19% vs SPY
  7. Aug 11, 202613w ago 8-K Bullish 7/10 Entry $49.87 to $52.44 Now $39.06 −21.68% ▲ +5.15% +5.56% vs SPY
  8. Jun 17, 202621w ago Insider Buy Neutral 2/10 Entry $29.24 to $27.72 Now $39.06 +33.58% ▼ −5.20% −3.53% vs SPY
  9. May 21, 202625w ago Press Release Neutral 5/10 Entry $26.30 to $28.50 Now $39.06 +48.52% ▲ +8.37% +6.52% vs SPY
  10. May 4, 202628w ago 8-K Neutral 4/10 Viewing Entry $25.00 to $25.90 Now $39.06 +56.24% ▲ +3.60% +1.62% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 7h 59m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 4, 2026